Go Pro
NASDAQ:PROF

Profound Medical Q2 2026 Earnings Report

Profound Medical logo
$6.99 +0.08 (+1.16%)
Closing price 04:00 PM Eastern
Extended Trading
$6.97 -0.02 (-0.29%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Profound Medical EPS Results

Actual EPS
N/A
Consensus EPS
-$0.22
Beat/Miss
N/A
One Year Ago EPS
N/A

Profound Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.75 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Profound Medical Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Thursday, August 6, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Profound Medical Earnings Headlines

BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel
Profound Medical (NASDAQ:PROF) Trading Up 1.6% - Time to Buy?
See More Profound Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Profound Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Profound Medical and other key companies, straight to your email.

About Profound Medical

Profound Medical (NASDAQ:PROF) Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia. The system features a closed-loop control mechanism that precisely adjusts ultrasound energy delivery based on continuous feedback from MR temperature mapping, enabling controlled ablation of prostate tissue while preserving surrounding structures.

Founded in 2015, Profound Medical has secured regulatory approvals and clearances in multiple jurisdictions, including CE mark certification for the European market and FDA clearance in the United States. The company has established a network of clinical partners and distributors across North America and Europe, where its technology is being adopted in leading cancer centers and urology clinics.

Profound Medical’s leadership comprises professionals with extensive experience in medical device development, clinical operations and regulatory affairs. The company continues to invest in research and development to expand its ultrasound platform for additional therapeutic indications and to support ongoing clinical studies aimed at improving patient outcomes.

View Profound Medical Profile